Troikaa Pharmaceuticals Ltd.
TypePrivate
IndustryPharmaceuticals
Founded1983
FounderMr. Rajni V. Patel
Headquarters
Ahmedabad, Gujarat
,
India
Area served
Worldwide
Key people
  • Dr. Ketan R. Patel (Chairman & managing director)
  • Mr. Milan R. Patel (Joint Managing Director)
ProductsPharmaceuticals, Branded and Generic drugs,
Number of employees
2300+ (2019)
Websitewww.troikaa.com

Troikaa Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Ahmedabad city of Gujarat, India.[1] It is a public unlisted company and is classified as company limited by shares.[2][3]

History

Troikaa Pharmaceuticals limited was established in 1983 in Ahmedabad, Gujarat by Rajni V. Patel, one of the few pharmacy graduates, of the first batch of L. M. College of Pharmacy, Ahmedabad in 1950. Ketan R. Patel is the current Chairman & Managing Director of the company. According to article, he was named as “India’s pain killer” for inventing world's first painless diclofenac injection, which helps alleviate acute pain and inflammation. Milan R. Patel is Joint Managing Director of the company.

In May 2020, Troikaa received US Patent for one of its products 'Dynapar QPS'.[4]

Operations

Troikaa has three manufacturing facilities in Gujarat and Uttarakhand certified by ISO 9001:2000 and WHO GMP (The World Health Organization for following Good Manufacturing Practices). Company has six marketing divisions & strength of more than 2300 employees. Company has presence in more than 70 countries.[5]

Troikaa secures its innovations related to Novel Drug Delivery systems through Patent co-operation treaty in more than 100 countries of the world.[6][7]

Litigation

In 2016, Troikaa Pharmaceuticals filed petition in Delhi High Court seeking license cancellation of Diclofenac Sodium Injection 75 mg/ml, manufactured by Themis Medicare Pvt Ltd and marketed by Novartis India Ltd. under the brand name Voveran 1ml.[8][9]

Troikaa Pharmaceuticals claimed that the diclofenac sodium 75 mg/ml injection contained Transcutol-P which caused damage to the kidneys. In July 2018, India's Drug Regulator canceled the license granted to M/S Themis Medicare for the sale of Diclofenac injection 75 mg/ml containing Transcutol-P.[10][11]

In 2012, Troikaa Pharmaceuticals suits a patent infringement in Ahmedabad district court against Ahmedabad-based Lincoln Pharmaceuticals and Delhi-based Akums Drug & Pharmaceuticals Ltd, saying the two companies had infringed upon its patented high concentration, low viscosity diclofenac injection. The case was continued by Gujarat High Court and ordered to Akums Drugs not to infringe as per the patent specification and dismissed Linclon Pharma's appeal.[12]

In 2008, Troikaa filed a suit for infringement of design against a company manufacturing D’ shaped tablets. The company had challenged that Troikaa's D-shaped tablet registration was invalid. The suit was transferred to the High Court of Gujarat and later in its first case under the Designs Act, the High Court decided in favor of the Troikaa.[13]

References

  1. ↑ "National Technology Day Celebration". pib.nic.in.
  2. ↑ Das, Sohini (1 October 2014). "Drug cos bet on NDDS for better price, market share". Business Standard India. Archived from the original on 17 June 2019. Retrieved 19 October 2023.
  3. ↑ "Troikaa's Dynapar QPS bags National Award". BPD. 10 June 2015. Archived from the original on 17 June 2019. Retrieved 19 October 2023.
  4. ↑ Correspondent, Special (21 May 2020). "Troikaa Pharma receives U.S. patent for Dynapar QPS". The Hindu. Archived from the original on 12 June 2020. Retrieved 19 October 2023.
  5. ↑ Reporter, B. S. (13 September 2010). "Troikaa Pharma gets patent approval for Dynapar AQ in CIS". Business Standard India. Archived from the original on 17 May 2021. Retrieved 19 October 2023.
  6. ↑ Reporter, B. S. (22 May 2015). "Troikaa Pharma commences work on Sanand plant; to make Dynapar". Business Standard India. Archived from the original on 30 August 2019. Retrieved 19 October 2023.
  7. ↑ Reporter, B. S. (2 December 2009). "Troikaa gets Australian patent for Dynapar AQ". Business Standard India. Archived from the original on 30 August 2019. Retrieved 19 October 2023.
  8. ↑ Raghavan, Prabha (19 May 2016). "Indian pharma company may sue drug controller over safety of Novartis painkiller". The Economic Times. Archived from the original on 1 August 2017. Retrieved 19 October 2023.
  9. ↑ Thacker, Teena (11 July 2018). "Drug regulator orders recall of Novartis's painkiller diclofenac". livemint.com. Archived from the original on 13 August 2022. Retrieved 19 October 2023.
  10. ↑ India, Press Trust of (12 July 2018). "Drug regulator cancels licence for Diclofenac sold by Novartis". Business Standard India. Archived from the original on 17 June 2019. Retrieved 19 October 2023.
  11. ↑ "'Novartis, Themis use unsafe ingredient' - BUSINESS & ECONOMY - News | News Syndication | Content Syndication". dnasyndication.com. Archived from the original on 2023-10-20. Retrieved 2023-10-19.
  12. ↑ Dutta, Vishal (30 April 2012). "HC grants relief to Troikaa in patent case; restrains two firms from selling Dynapar injections". The Economic Times. Archived from the original on 20 October 2023. Retrieved 19 October 2023.
  13. ↑ Reddy, Prashant. "Gujarat High Court grants interim injunction in Designs Case". SpicyIP. Archived from the original on 2021-01-31. Retrieved 2023-10-19.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.